McIlrath & Eck LLC Buys 140 Shares of Eli Lilly and Company (NYSE:LLY)

McIlrath & Eck LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 29.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 621 shares of the company’s stock after purchasing an additional 140 shares during the quarter. McIlrath & Eck LLC’s holdings in Eli Lilly and Company were worth $479,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in LLY. Grassi Investment Management increased its position in Eli Lilly and Company by 0.3% in the fourth quarter. Grassi Investment Management now owns 79,512 shares of the company’s stock worth $61,383,000 after purchasing an additional 225 shares during the last quarter. Elevate Capital Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth $262,000. Capital & Planning LLC increased its holdings in shares of Eli Lilly and Company by 15.6% in the 4th quarter. Capital & Planning LLC now owns 481 shares of the company’s stock worth $371,000 after buying an additional 65 shares during the last quarter. J2 Capital Management Inc bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $357,000. Finally, Oak Ridge Investments LLC raised its position in shares of Eli Lilly and Company by 6.2% during the 4th quarter. Oak Ridge Investments LLC now owns 55,243 shares of the company’s stock valued at $42,648,000 after buying an additional 3,201 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on LLY shares. Guggenheim reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. HSBC cut Eli Lilly and Company from a “buy” rating to a “reduce” rating and dropped their target price for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target on the stock. Truist Financial raised their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Finally, UBS Group reduced their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,011.37.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $745.72 on Wednesday. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The stock’s fifty day moving average price is $795.44 and its 200-day moving average price is $804.82. The firm has a market cap of $706.75 billion, a P/E ratio of 63.68, a P/E/G ratio of 1.40 and a beta of 0.48. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.58 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a $1.50 dividend. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.80%. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.13% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.